Cargando…
Prevention of chemotherapy-induced left ventricular dysfunction
Prevention of left ventricular dysfunction predominantly induced by anthracyclines and/or trastuzumab still represents a challenge for cardio-oncology today. Indeed, this complication threatens to limit the significant gain in cancer survival achieved to date. Oncology strategies with cumulative dos...
Autores principales: | Bisceglia, Irma, Canale, Maria Laura, Cartoni, Domenico, Matera, Sabrina, Petrolati, Sandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876299/ https://www.ncbi.nlm.nih.gov/pubmed/35233212 http://dx.doi.org/10.1093/eurheartj/suab085 |
Ejemplares similares
-
Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect?
por: Bisceglia, Irma, et al.
Publicado: (2023) -
Concepts in cardiac oncology
por: Bisceglia, Irma, et al.
Publicado: (2020) -
Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer
por: Yoon, Hyun Ju, et al.
Publicado: (2016) -
Subclinical Left Ventricular Dysfunction During Chemotherapy
por: Nicol, Martin, et al.
Publicado: (2019) -
Comment on “Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)